New Blood Test for Cancer Moves Closer to Approval

A group of independent experts has taken a major step toward changing how we detect cancer. On Wednesday, an advisory panel for the Food and Drug Administration (FDA) voted to support the approval of a new blood test called Galleri. This test, created by a company named Grail, is designed to find up to 50 different types of cancer by looking for genetic material in a person's blood. Currently, many of these cancers are not checked for during regular doctor visits.

The panel’s vote is a significant moment for the medical industry. According to NPR, the FDA often follows the advice of its expert panels, although it is not required to do so. The experts voted 10 to 0 to confirm that the test is safe. They also voted 6 to 4 that the test is effective, and 7 to 2 that the benefits of using the test are greater than the risks for the patients it is intended for. This decision marks the first time a multi-cancer blood test has moved this far in the FDA’s official review process.

Why is this test important? Many doctors and patients hope that new technology will help find cancer earlier, when it is often easier to treat. NPR reports that there are hundreds of companies working on similar blood tests. These tests work by finding signs of cancer that the body releases into the blood or saliva. Grail says that its test is meant to be used alongside standard screenings, such as colonoscopies and mammograms, rather than replacing them. If the FDA gives its final approval, it could lead to insurance companies paying for the test, which currently costs $949.

The review process for Galleri was not simple. The FDA asked the committee to look closely at whether the test is reliable and if it finds cancer early enough to be useful. The agency also expressed concerns about the risk of "false results." A false negative might lead a patient to believe they are healthy when they actually have cancer, while a false positive might cause unnecessary worry or extra medical tests. Because of this, the FDA may require Grail to include clear warnings in its marketing materials to explain these risks to patients.

To make their decision, the committee reviewed two large studies. One study included more than 140,000 patients in the United Kingdom, and another involved over 35,000 patients in North America, all of whom were over the age of 50. According to NPR, the results of these studies were a subject of debate. While the tests did not meet the main goal of reducing the total number of deaths, the company provided further information to help the panel understand the data better.

Industry experts are watching this situation closely. Cristian Tomasetti, a director at the City of Hope cancer center, noted that if the FDA approves the test, it would show that the industry's approach to early cancer detection is valid. He described this as a "new era" for medicine. Because the FDA decided to speed up its review of Galleri, it is currently the leader in this field. The outcome of this process is seen as a sign of what might happen for other companies trying to develop similar technology.

While the panel's support is a big win for Grail, the final decision remains with the FDA. If the agency grants approval, it will be a landmark moment for cancer screening. For now, patients and doctors must wait to see if the FDA agrees with its advisors. If it does, it could provide a new tool in the fight against cancer, potentially saving lives by catching the disease before it becomes too difficult to manage. For many, this represents the hope that simple blood tests could one day become a regular part of staying healthy.